Comparison of Two Routes of Administration of a Multimodal Analgesic Protocol in Postoperative Cesarean Section

Sponsor
Centre de Maternité de Monastir (Other)
Overall Status
Completed
CT.gov ID
NCT03626753
Collaborator
(none)
200
1
2
5.9
33.8

Study Details

Study Description

Brief Summary

Many drugs with various mechanisms of action are used for postcaesarean pain relief. Although the response to pain relief is sometimes believed to be individual, it is very important to establish the most effective with the least adverse effects type of oral analgesia for women after caesarean section. Optimal pain control post-caesarean section will benefit not only the mother and her baby, but also a healthcare system. Optimal pain control may shorten the time spent in hospital after caesarean section and, therefore, reduce healthcare costs.

Condition or Disease Intervention/Treatment Phase
  • Drug: Nefopam 20 MG/ML
  • Drug: "Nefopam (Acupan)" 20 MG/ML Injectable Solution
  • Drug: "Acetaminophen, (paracetamol)" 500Mg Tab
  • Drug: (Acetaminophen "paracetamol") IV Soln 10 MG/ML
  • Drug: (Piroxicam "piroxan") 20 MG Oral Tablet
  • Drug: (Piroxicam "piroxan") 20Mg/1mL Injection
Phase 2/Phase 3

Detailed Description

Pain after cesarean section (CS), usually described as strong, is an obstacle to good mother-child interaction and post-operative rehabilitation. Its management is important for a quick recovery and allow the mother to take care and link with her newborn. Currently, intrathecal opioids are the most commonly used technique and provide the foundation for post-cesarean analgesia. This technique combined with multimodal analgesia reduces the doses of morphine consumed, including these side effects. Spinal anesthesia is the standard anesthetic technique for caesarean section; it offers several advantages including the possibility of prescribing oral analgesics. An ideal analgesic protocol is one that is simple to implement, cost-effective, and has minimal impact on the work staff. It would have a good safety profile, a low incidence of side effects and complications, and respond to wide inter-patient variability. It relieves the mother of high quality pain while having minimal interference with her, newborn care and anesthesia while allowing safe breastfeeding.

The aim of this work is to compare the quality of an multimodal oral analgesia with intravenous analgesia and to demonstrate non-inferiority of the oral route pain relieve in postoperative caesarean section period. The secondary objectives was to evaluate the maternal tolerance of the drugs (piroxicam, nefopam, paracetamol) used postoperatively of a caesarean section.

Study Design

Study Type:
Interventional
Actual Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Comparison of Two Routes of Administration of a Multimodal Analgesic Protocol in Postoperative Cesarean Section Oral vs Intravenous
Actual Study Start Date :
Jan 1, 2015
Actual Primary Completion Date :
Jun 30, 2015
Actual Study Completion Date :
Jun 30, 2015

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Oral Group

received in post operative period oral analgesia ( "nefopam (Acupan)" 20mg/6h, "piroxicam (piroxan)" 40mg/24h," Acetaminophen (paracetamol)" 1g/6h)

Drug: Nefopam 20 MG/ML
given by Oral route the dose of 20mg every 6 hours.
Other Names:
  • 2 ampoule
  • Drug: "Acetaminophen, (paracetamol)" 500Mg Tab
    2 tablets of "Acetaminophen (paracetamol)" 500Mg Tab administrated orally every 6 hours.
    Other Names:
  • 2 tablets
  • Drug: (Piroxicam "piroxan") 20 MG Oral Tablet
    2 tablets of "piroxicam (piroxan)" administrated orally once per 24 hours.
    Other Names:
  • 2 tablets
  • Active Comparator: Intravenous group

    received in post operative period intravenous analgesia ( "nefopam (Acupan)" 20mg/6h, "piroxicam (piroxan)" 40mg/24h," Acetaminophen (paracetamol)" 1g/6h)

    Drug: "Nefopam (Acupan)" 20 MG/ML Injectable Solution
    given by intravenous route at the dose of 20mg every 6 hours.
    Other Names:
  • 2 ampoule
  • Drug: (Acetaminophen "paracetamol") IV Soln 10 MG/ML
    Acetaminophen IV Soln 10 MG/ML, 1g paracetamol administrated intravenously every 6 hours.
    Other Names:
  • 1 ampoule: 1g
  • Drug: (Piroxicam "piroxan") 20Mg/1mL Injection
    2 ampoules of (piroxicam "piroxan") administrated intravenously once per 24 hours.
    Other Names:
  • 2 ampoules
  • Outcome Measures

    Primary Outcome Measures

    1. Visual Analogue Scale (VAS) pain [24 hours postoperative]

      from 0 - 10 (with 0 being no pain and 10 being the most severe pain imaginable) at rest and coughing or mobilization

    Secondary Outcome Measures

    1. morphine consumption [24 hours postoperative]

      morphine consumption

    2. sides effects [24 hours postoperative]

      the occurrence of any undesirable effects related to the administration of any of the 3 drugs (nausea, vomiting, diarrhea, malaise, hypotension, sweating, convulsion, dryness of the mouth, tachycardia, palpitations, vertigo, allergic reactions)

    3. postoperative complications [24 hours post operative]

      The occurrence of a postoperative complication (postpartum haemorrhage, blood transfusion, hysterectomy, etc).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Pregnant in singleton pregnancy with gestational age > 34 weeks

    • American society of anesthesiologists (ASA) physical status I-II.

    Exclusion Criteria:
    • history of gastrointestinal disorders predisposing to bleeding disorders such as ulcerative colitis,

    • Crohn's disease,

    • gastrointestinal cancers or diverticulitis,

    • an active peptic ulcer,

    • an inflammatory gastrointestinal disorder or a gastrointestinal haemorrhage,

    • parturients who present preeclampsia,

    • premature delivery (<32 weeks),

    • constitutional or acquired coagulopathy,

    • An antecedent of hemorrhage of the delivery,

    • a hemorrhagic complication postoperatively,

    • Anemia (hemoglobin less than 8g / 100ml),

    • conversion of spinal anesthesia into general anesthesia,

    • women with severe medical conditions: renal failure (preoperative creatinine clearance <30ml / min), heart or liver failure.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centre de Maternité de Monastir Monastir Tunisia 5000

    Sponsors and Collaborators

    • Centre de Maternité de Monastir

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Fethi Jebali, Medical doctor, clinical professor of Anesthesiology and intensive care medecine, Centre de Maternité de Monastir
    ClinicalTrials.gov Identifier:
    NCT03626753
    Other Study ID Numbers:
    • CMNMonastir
    First Posted:
    Aug 13, 2018
    Last Update Posted:
    Aug 15, 2018
    Last Verified:
    Aug 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Fethi Jebali, Medical doctor, clinical professor of Anesthesiology and intensive care medecine, Centre de Maternité de Monastir
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 15, 2018